Detection of human liver-specific F antigen in serum and its preliminary application *

FENG Tao¹, ZENG Zhao-Chun², ZHOU Lan², CHEN Wen-Yuan¹ and ZUO Yu-Ping¹

Subject headings  liver-specific F antigen/blood; liver neoplasms/diagnosis; carcinoma, hepatocellular/diagnosis; liver diseases/diagnosis

INTRODUCTION
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activity are usually used as biochemical criteria for the evaluation of liver lesion. These enzymes will release into the blood when the integrity of hepatocyte is compromised. Although the aminotransferase has been used as a criterion of liver function for decades, it can not show the accurate hepatohistological characteristics when it is abnormal in patients with chronic liver disease[1].

Human liver-specific F antigen (F-Ag), a Mᵣ 44 000 cytosolic protein of unknown function, is found predominantly in the liver. Previous studies using relatively insensitive assays have shown that the concentration of F-Ag in the serum rises when the liver is severely damaged[2]. The sensitive radi oimmunoassay of hepatocellular damage[1]. To avoid the effects of rad ioactive isotope, Biotin-Avidin ELISA (BAEILSA) was established to detect F-Ag, and its clinical value as guidelines of liver function was discussed and compared with that of AST and α-AFP.

MATERIALS AND METHODS
Methods
Preparation of biotin-IgG (B-IgG) Oneg/L BNHS (resolv ed in N, N-dimethyl formamide) and purified human F-Ag was used as the standard. F-Ag antibody (guinea pig against human F-Ag antiserum) was prepared by our department (1:32). D-biotin-N-hydroxysuccinimi-dyl esters (BNHS) and avidin-HRP (A-HRP) were provided by Shanghai Biochemistry Institute and Chemistry Department of Shanghai Medical University respectively.

BA-ELISA Coating 96-well plate was coated with anti-F-Ag IgG (5 mg/L, 200 µL/well) for 60 min. The substrate reaction was stopped by 2 mol/L H₂SO₄ (50 µL/well). The OD value of each well was measured in triplicate.

Detection of α-AFP and AST ELISA (normal value <20 μg/L) and routine assay of AST (normal value 5U/ L - 35U/L) were used.

Statistical method  t test and correlative analysis

1Department of Biochemistry, Chongqing University of Medical Sciences, Chongqing, 400016, China
2Department of Molecular Biology, Chongqing University of Medical Sciences, Chongqing 400016, China
FENG Tao, male, born on 1963-07-26 in Maerkang City, Sichuan Province, Han nationality, graduated from Beijing Normal University in 1984 and earned master’s degree in Chongqing Medical University in 1991, lecturer of Biochemistry, majoring purification and production of antiserum of protein, having 5 papers published.

*Supported by the Educational Committee of Sichuan Province.
Correspondence to: FENG Tao, Department of Biochemistry, Chongqing Medical University, Chongqing 400016, China
Tel. +86 • 23 • 68808038, Fax. +86 • 23 • 68817090
Received 1998-12-21

© 1999 by the WJG Press  ISSN 1007-9327

World Journal of Gastroenterology
were made by computer.

RESULTS

BA-ELISA

The minimum detection limit of BA-ELISA was 0.01U/mL (1U = 1.0 µg F-Ag). The linear range of the standard curve was 0.01U/mL-50U/mL. The intra-and inter-assay coefficient of variation (CV) was 6.2% and 7.7% respectively. Recovery rate was 95.9%-105.2% when the known amount of F-Ag was put into the serum of normal subjects. All serum samples were detected with BA-ELISA, and the results were shown in the following Table 1. The serum F-Ag concentration of 25 healthy subjects was 0.08 U/mL ± 0.03 U/mL. The values under 0.08 U/mL ± 0.03 U/mL were regarded as negative. Compared with control group (healthy subjects), increase was found in the serum F-Ag of all liver diseases with no change in non-liver diseases (P > 0.05). AST activity was 124.5 U/L ± 62.5 U/L in non-carcinomatous liver diseases (31 cases). No obvious correlation was found between their AST activity and serum F-Ag concentration (n = 31, r = 0.13, P > 0.05). AST activity was 91.5 U/L ± 47.8 U/L in acute hepatitis (8 cases). A close correlation was found between their AST activity and serum F-Ag concentration (n = 8, r = 0.89, P < 0.05). AST activity was 91.5 U/L ± 47.8 U/L in acute hepatitis (8 cases). A close correlation was found between their AST activity and serum F-Ag concentration (n = 8, r = 0.89, P < 0.05). AST activity was 91.5 U/L ± 47.8 U/L in acute hepatitis (8 cases). A close correlation was found between their AST activity and serum F-Ag concentration (n = 8, r = 0.89, P < 0.05). AST activity was 91.5 U/L ± 47.8 U/L in acute hepatitis (8 cases).

Table 1 The serum F-Ag concentration of liver diseases and non liver diseases

| Groups                  | Total cases | Positive cases | Positive rate (%) | F-Ag (CAS, U/mL) |
|-------------------------|-------------|----------------|-------------------|------------------|
| Control                 | 25          | 0              | 0.00              | 0.08±0.03        |
| Acute hepatitis         | 8           | 7              | 87.5              | 9.43±4.02        |
| Chronic hepatitis       | 10          | 8              | 80.0              | 6.72±3.17        |
| Hepatocellular cancer   | 23          | 21             | 91.3              | 15.15±5.48       |
| Liver cirrhosis         | 8           | 6              | 75.0              | 8.31±3.59        |
| Alcoholic liver diseases| 5           | 4              | 80.0              | 5.28±2.64        |
| Non-liver diseases      | 10          | 1              | 10.0              | 0.11±0.04        |

Table 1 The serum F-Ag concentration of liver diseases and non liver diseases

1P<0.05; 2P<0.01.

DISCUSSION

Making use of high affinity between biotin and avidin (Kd = 10^{-15} mol/L), we coupled biotin with anti-F-Ag IgG and developed BA-ELISA for detecting F-Ag of human serum which is highly sensitive, stable (recovery rate 95.9%-105.2%), easy and safe with a wide range (0.01 U/mL-50 U/mL). It is advisable for clinical use.

Positive serum F-Ag was found in 46 out of 54 cases of liver disease (its average level was 13.5 U/mL and its positive rate was 85.2%), while positive serum F-Ag was found in only 1 out of 10 cases of non-liver diseases. It indicates that F-Ag is rather specific and has a high detectable rate for liver disease. Compared with present criteria for the evaluation of liver function, serum F-Ag level is correlated with AST activity in acute hepatitis patients, and is not correlated with AST activity in patients with chronic hepatitis, liver cirrhosis and cancer. It is suggested that F-Ag is of great practical value to the diagnosis, treatment and prognosis of liver diseases, and is a more sensitive and specific marker of liver damage and pathological features as compared with the routine criteria of liver function.

The detectable rate of serum F-Ag was 91.3% in 23 cases of liver cancer. The level of serum F-Ag was higher (the mean level was 14.3 U/mL) than that of other liver diseases. Serum F-Ag was negative in 4 cases of non-liver tumors out of 10 cases of non-liver disease, which was consistent with that of stomach cancer reported by Grewal[3]. It is suggested that serum F-Ag is a specific marker of liver tumor and has a high detectable rate. The level of F-Ag and α-AFP has a positive correlation. Therefore, detection of serum F-Ag is helpful for the correct diagnosis of liver diseases.

Further research is to be made in the function of F-Ag in order to find out the direct evidences and theoretical bases of F-Ag as a marker of liver damage.

REFERENCES

1 Foster GR, Goldin RD, Oliveira DBG. Serum F protein: a new sensitive and specific test of hepatocellular damage. *Clinica Chimica Acta*, 1989;184:85-92
2 Mori Y, Mori Y, Isato K, Ueda S, Wakashin Y, Wakashin M, Okuda K. Purification and immunological characterization of human liver-specific F antigen. *Clinica Chimica Acta*, 1981;112:125-134
3 Grewal GK, Oliveira DBG. Why serum F protein is a sensitive and specific marker of liver damage in man. *Clinica Chimica Acta*, 1990;191:93-96

Edited by WANG Xian-Lin